Mounjaro generic availability?

When Will Mounjaro Have a Generic Version?

Mounjaro, also known as tirzepatide, is a novel glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist developed by Eli Lilly and Company.

What are the Obstacles to Generic Approval?

One of the main obstacles to generic approval is the complex patent situation surrounding Mounjaro. As of now, Eli Lilly's patent protecting Mounjaro is valid until at least 2033, according to a listing on DrugPatentWatch.com [1]. The patent expiration date might change if additional patent extensions are granted. Therefore, generic manufacturers have to wait until this patent expires before they can launch their versions in the market.

What are Biosimilars?

Biosimilars are biologically-derived products that are similar to existing biologic products. Although they may not be exact replicas, they are designed to have the same therapeutic effects. However, biosimilars typically need to undergo a separate clinical trial before they can be approved by regulatory agencies like the FDA. In case of a product like Mounjaro, there is an ongoing debate about whether a biosimilar can be approved before the patent expires for the original drug. However, some argue that biosimilars can enter the market before patent expiry as there is no requirement that they be made after that date [2].

When Will Mounjaro's Patent Expire?

According to the patent watch list by DrugPatentWatch.com, Mounjaro's patent expiration date for the United States is listed as 2033 [1]. As patents can provide extended exclusivity to a pharmaceutical product, it's challenging to estimate the exact timeline until a generic version is available. However, as soon as the patent expires, it's possible that several generic companies can initiate the process to obtain approval to market their own versions of Mounjaro.

Competitor's Products and Timeline

Other pharmaceutical companies like Novo Nordisk, have already entered the market for GLP-1 receptor agonists with their product Ozempic/Semaglutide. Other pharmaceutical companies, like Sanofi and AstraZeneca, are also working on developing similar GLP-1/GLP-1 receptor agonists. It would not be surprising if generic versions of Mounjaro will become available after its patent expiration, especially if they demonstrate comparable efficacy and safety to the original product.

Sources:
[1] DrugPatentWatch.com
[2] Journal article on Biosimilars